drugset
drugset / Trial / NCT06911827

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

NCT06911827 ↗

Phase 1/2 Recruiting 149 enrolled Qilu Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of QLP2117 in combination with QL2107 in Advanced Solid Tumor Patients.

Timeline

Start
2025-05-09
Primary completion
2027-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject QL2107 Unknown — —
Subject QLP2117 Unknown — —

Indications

neoplasm